Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer
about
The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?Radiotherapy and the tumor stroma: the importance of dose and fractionationGastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation TherapyTechnology for Innovation in Radiation OncologyNew challenges in high-energy particle radiobiology.Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects.Update on treatment of liver metastases: focus on ablation therapies.Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation: Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery.Opportunities for Radiosensitization in the Stereotactic Body Radiation Therapy (SBRT) EraRadiobiological basis of SBRT and SRS.Radiobiology of stereotactic body radiation therapy (SBRT).Will intrafraction repair have negative consequences on extreme hypofractionation in prostate radiation therapy?Predicting liver SBRT eligibility and plan quality for VMAT and 4π plansDurable control of locally recurrent renal cell carcinoma using stereotactic body radiotherapy.Dose escalation, not “new biology,” can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. In regard to Brown et al.In regards to decision making for reirradiation of a recurrent intramedullary spinal cord metastasis.A feasibility study: Selection of a personalized radiotherapy fractionation schedule using spatiotemporal optimization.
P2860
Q26823489-0C11ECD9-F445-44EC-85FC-E80AD5E0B77FQ27022685-6F273D11-F41B-4EF1-A1F3-ABC447D39683Q28086904-94C02DB5-218B-462D-BAF2-B03D111BFA49Q28610710-A203A0AD-1CD9-4F8A-9B58-877EF07B3745Q33782346-D2703439-48BD-4403-9542-85AF0895663AQ35078406-7FDCC73B-A32E-4C65-8246-18AF37FC03ADQ35443517-606AAE00-1E06-4DAB-A71A-5E759F9CB47FQ36509821-BE5634FD-8325-41E5-8EDC-1DA1D9F8DC43Q37118895-0793F27F-2CC7-4F7E-92FE-426844C292F5Q38226118-5311A255-6208-4CAA-B0F5-BF01FEE776BCQ38685466-3B20C3E7-6C71-491B-8CEB-37E4AF664B6CQ40452434-F7496D50-C1FE-4594-8997-F91B7A71A8DBQ41992922-FEBF3ADA-B849-4836-9E23-8322B65611D9Q42725545-8267194E-ED2D-4FCB-AE06-FD5B8A252A75Q42915037-8AAB0110-B71E-4384-92A6-32E84A62CAE9Q47146566-22479774-9204-4F0A-BD8F-BA74A337578BQ51664383-D2408C5F-5D1E-4BF5-AFA5-E760AC789D3C
P2860
Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Dose escalation, not "new biol ...... ith non-small cell lung cancer
@en
Dose escalation, not "new biol ...... th non-small cell lung cancer.
@nl
type
label
Dose escalation, not "new biol ...... ith non-small cell lung cancer
@en
Dose escalation, not "new biol ...... th non-small cell lung cancer.
@nl
prefLabel
Dose escalation, not "new biol ...... ith non-small cell lung cancer
@en
Dose escalation, not "new biol ...... th non-small cell lung cancer.
@nl
P2093
P2860
P1476
Dose escalation, not "new biol ...... ith non-small cell lung cancer
@en
P2093
David J Brenner
David J Carlson
J Martin Brown
P2860
P304
P356
10.1016/J.IJROBP.2012.11.003
P407
P577
2013-04-01T00:00:00Z